Auro Laboratories Limited has submitted announcement for appointment of Chief Financial Officer.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.3 pts more than Nifty Microcap 250 and 4.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Auro Laboratories' Board, at its May 30, 2025 meeting, approved three key items: (1) the appointment of Mr. Kuntal Pancholi (29+ years of experience in Accounts & Finance) as the new Chief Financial Officer and Key Managerial Personnel effective May 30, 2025; (2) the appointment of M/s. Pokharna and Associates, Chartered Accountants, as Internal Auditors for FY 2025-26; and (3) the Audited Financial Results for Q4 and full year ended March 31, 2025, with the statutory auditor issuing an unmodified opinion. For FY25, total income rose modestly to ₹551.39 lakh from ₹536.35 lakh, but profit after tax fell sharply to ₹18.39 lakh from ₹77.92 lakh, with EPS dropping to ₹2.95 from ₹12.50. Total assets grew to ₹990.96 lakh, with non-current borrowings rising significantly to ₹330.85 lakh (from ₹183.78 lakh) and capital work-in-progress at ₹564.75 lakh, indicating ongoing capex.
Sharp decline in profitability despite stable topline and rising debt/capex may concern investors, though the new CFO brings seasoned finance leadership. The clean audit opinion and continuity in governance are positives, but the steep earnings drop warrants close scrutiny on margin pressure and capital deployment.